Family teashop reopens in a pub
A teashop, which was located in a shopping centre for more than 50 years, has reopened in a pub.
Robby's Tea Shop launched in 1972 in The Arndale - now called Luton Point - in Luton town centre, Bedfordshire, but closed down last month following discussions about "rent".
Owner Denise Clayburn, 46, said people were upset "as everyone had such fond memories, their children and grandchildren had all grown up with it and it was sad to see".
After she announced the closure on social media, the new owner of the George II pub in Bute Street offered her a space in the pub.
The teashop was set up by Ms Clayburn's father-in-law, who named it after his son, her late husband, who was called Rob.
She said: "It is more than just a teashop, people have grown up with it, people who have lost their partners, it is somewhere where people feel comfortable."
Ms Clayburn said the only thing that would be majorly different at the new location was food choice and added: "We don't have the cakes we had in the teashop."
"The staff are all still here - it is just a different environment."
Ms Clayburn thanked the community, which had supported them for 53 years.
"The teashop would never have lasted this long without our loyal customers - they are the ones who make it."
Follow Beds, Herts and Bucks news on BBC Sounds, Facebook, Instagram and X.
Luton Town legend visits new pub wall mural
Landlord speaks out after pub sign goes viral
Luton Point
British Independent Retailers Association
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 hours ago
- Bloomberg
All the Wrong Moves for British Homeowners
When it comes to housing policy, the British government motto ought to be: We have met the enemy and it is us. The law of unintended regulatory, fiscal and monetary consequences has stopped investment in its tracks. Left to its own devices, the market functions pretty well. But right now, for everyone from the homeless to first-time buyers, it's essentially paralyzed.
Yahoo
2 hours ago
- Yahoo
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT therapy approved in China, following recent granting of Priority Review by CDE Additional applications planned in the US and other markets around the world Not intended for UK-based media DARMSTADT, Germany, June 10, 2025--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company's application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., also has been granted breakthrough therapy designation (BTD) by the NMPA. "With the acceptance of our application for pimicotinib and the initiation of the priority review, we aim to offer patients in China the first approved systemic therapy for TGCT, addressing a tremendous unmet need in this country," said Hong Chow, Head of China and International, Healthcare business of Merck KGaA, Darmstadt, Germany. "Pimicotinib has demonstrated the ability to not only shrink tumors that affect their joints but also improve outcomes like mobility, pain and stiffness, highlighting its potential to be a best-in-class treatment for TGCT. In parallel, we are working to file a New Drug Application to the US Food and Drug Administration, with additional filings planned in other markets." TGCT is a locally aggressive and often recurring tumor of the joints that can cause high morbidity associated with swelling, pain, stiffness, and limited mobility of the affected joints, significantly impacting daily activities and quality of life in the primarily working-age population that it affects. If left untreated or in recurrent cases, TGCT can result in irreversible damage to the bone, joint and surrounding tissues. This highlights the need for well-tolerated and effective systemic treatments that can impact tumor growth while relieving the symptoms of the disease. The application is based on results from Part 1 of the global Phase 3 MANEUVER study, in which once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) compared with placebo at week 25 (54.0% vs. 3.2% for placebo; p<0.0001). The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain. The data were presented earlier this month at the 2025 ASCO Annual Meeting. About MANEUVERThe pivotal Phase 3 MANEUVER study is a three-part, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pimicotinib in patients with TGCT who require systemic therapy and have not received prior anti-CSF-1/CSF-1R therapy. The study is being conducted by Abbisko Therapeutics in China (n=45), Europe (n=28), and the US and Canada (n=21). In the double-blind Part 1, 94 patients were randomized 2:1 to receive either 50 mg QD of pimicotinib (n=63) or placebo (n=31) for 24 weeks. The primary endpoint is objective response rate (ORR) at week 25, as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by blinded independent central review in the intent-to-treat (ITT) population. Secondary endpoints include tumor volume score, active range of motion, stiffness by Numeric Rating Scale (NRS), pain by Brief Pain Inventory (BPI), and physical function measured by Patient-Reported Outcomes Measurement Information System (PROMIS). After the double-blind Part 1, eligible patients could continue to the open-label Part 2 for up to 24 weeks of dosing, results of which are expected in mid-2025. Patients who complete Part 2 may then enter the open-label extension phase (Part 3) for extended treatment and safety follow-up. About Pimicotinib (ABSK021)Pimicotinib (ABSK021), which is being developed by Abbisko Therapeutics, is a novel, orally administered, highly selective and potent small-molecule inhibitor of CSF-1R. Pimicotinib was recently granted Priority Review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for the treatment of patients with tenosynovial giant cell tumor (TGCT) who require systemic therapy. Pimicotinib has been granted breakthrough therapy designation (BTD) by China National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and priority medicine (PRIME) designation from the European Medicines Agency (EMA). Merck KGaA, Darmstadt, Germany, holds worldwide commercialization rights for pimicotinib. Advancing the Future of Cancer CareAt Merck KGaA, Darmstadt, Germany, we strive every day to improve the futures of people living with cancer. Building on our 350-year global heritage as pharma pioneers, we are focusing our most promising science to target cancer's deepest vulnerabilities, pursuing differentiated molecules to strike cancer at its core. By developing new therapies that can help advance cancer care, we are determined to create a world where more cancer patients will become cancer survivors. Learn more at About Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to to register for your online, change your selection or discontinue this service. View source version on Contacts Media Relations Phone: +1 (781) 427-4351 Investor Relations Phone: +49 6151 72-3321 Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
London-listed Spectris soars 20% on fresh takeover interest from Advent
-- Shares of Spectris PLC (LON:SXS) surged by over 20% in London trading following a Bloomberg News report that private equity firm Advent is considering a takeover of the UK-based precision and testing equipment maker. The potential acquisition comes as Spectris shares had previously dropped about 18% this year, valuing the company at around £2 billion ($2.8 billion). Spectris, which employs 7,600 people across more than 30 countries, specializes in developing high-tech instruments, testing equipment, and software for various industries, including life sciences, automotive, electronics, and semiconductors. Asia is a significant market for Spectris, contributing to about 36% of its revenue last year, with Europe and North America following closely. This news of potential acquisition interest comes after a failed takeover attempt by Bain Capital and Advent International in 2018, which was abandoned amid the political uncertainties brought on by Brexit. Under the leadership of CEO Andrew Heath, Spectris has been streamlining operations since 2018, focusing on its core business in the scientific and dynamics divisions. This strategic shift followed a decline in first-quarter sales due to weakened demand in key sectors such as automotive and semiconductors. Despite the challenging market conditions, Spectris has been optimistic about mitigating the impacts of tariffs and achieving strong growth in adjusted operating profit by 2025. Related articles London-listed Spectris soars 20% on fresh takeover interest from Advent AppLovin would be more valuable without its 1P games, Morgan Stanley argues Morgan Stanley downgrades Lululemon on weak US growth outlook
